SCHEMBL267158

SCHEMBL267158

Cc1c(Nc2cccc(C(F)(F)F)c2)nc(N)nc1-c1ccc(OCCN2CCCC2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC2A1 P11166 1/20 0.51
▸ LTA4H P09960 3/20 0.51
▸ BACE1 P56817 1/20 0.47
▸ SRC P12931 5/20 0.45
▸ ADORA2A P29274 4/20 0.45
▸ ADORA1 P30542 4/20 0.45
▸ BRD4 O60885 3/20 0.45
▸ JAK2 O60674 5/20 0.45
▸ JAK3 P52333 4/20 0.45
▸ BRDT Q58F21 2/20 0.45
▸ BRD2 P25440 1/20 0.45
▸ BRD3 Q15059 1/20 0.45
▸ HRH3 Q9Y5N1 3/20 0.44
▸ JAK1 P23458 2/20 0.43
▸ PTK2 Q05397 2/20 0.43
▸ ABL1 P00519 2/20 0.43
▸ EGFR P00533 2/20 0.43
▸ LCK P06239 2/20 0.43
▸ FYN P06241 2/20 0.43
▸ YES1 P07947 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL265183 0.92 BRD4 (0.47) SLC2A1LTA4HSRCADORA2AADORA1
SCHEMBL266270 0.90 LTA4H (0.52) SLC2A1LTA4HBACE1SRCADORA2A
SCHEMBL264781 0.89 ADORA2A (0.46) SLC2A1LTA4HSRCADORA2AADORA1
SCHEMBL265050 0.87 LTA4H (0.48) LTA4HBACE1SRCADORA2AADORA1
SCHEMBL266079 0.85 BRD4 (0.57) SLC2A1SRCADORA2AADORA1BRD4
SCHEMBL265641 0.85 AXL (0.47) SLC2A1BACE1SRCADORA2AADORA1
SCHEMBL265711 0.83 LTA4H (0.52) LTA4HSRCADORA2AADORA1BRD4
SCHEMBL266734 0.83 SRC (0.49) LTA4HBACE1SRCADORA2AADORA1
SCHEMBL265815 0.82 AXL (0.51) BACE1SRCADORA2AADORA1HRH3
SCHEMBL264515 0.78 BRD4 (0.71) SLC2A1LTA4HBACE1SRCADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8604042-B2 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2013-12-10 — — US disclosed
US-8138199-B2 Use of bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2012-03-20 — — US disclosed
US-8133900-B2 Use of bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2012-03-13 — — US disclosed
US-20110212077-A1 BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES TARGEGEN, INC. (US) 2011-09-01 — — US disclosed
US-7825246-B2 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2010-11-02 — — US disclosed
US-20090275582-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases IMPACT BIOMEDICINES, INC. 2009-11-05 — — US disclosed
US-7528143-B2 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2009-05-05 — — US disclosed
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-11-08 — — US disclosed
US-20070191405-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-08-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191405-A1 Bi-aryl meta-pyrimidine inhibitors of kinases JAK2, TYK2, JAK3 SLC2A1 4727/4885LTA4H 3846/4885BACE1 4739/4885
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases JAK2, TYK2, JAK3 SLC2A1 4727/4885LTA4H 3846/4885BACE1 4739/4885
US-20090275582-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases JAK2, TYK2, JAK3 SLC2A1 4727/4885LTA4H 3846/4885BACE1 4739/4885
US-20110212077-A1 BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES JAK2, TYK2, JAK3 SLC2A1 4727/4885LTA4H 3846/4885BACE1 4739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback